Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Eye Cancer: early-phase trial registry
2 of 3 indexed Eye Cancer trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #5,209 of 28,707 conditions by registered trial count.
3 US clinical trials · 2 currently recruiting · #5,209 of 28,707 conditions by registered trial count
Eye Cancer: 3 US clinical trials tracked, 2 recruiting.
Eye Cancer is the subject of 3 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is Novelwise Pharmaceutical Corporation, running 1 of these trials.
Enrollment posture brief
Registry condition eye-cancer
OPEN 2 | RECR 67% | LATE 0 | EARLY 2 | RANK #5209 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Acute Hypoxemic Respiratory Failure (67% recruiting · 6 trials)
Eye Cancer lists 2 open slots (67% of 3 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Eye Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Eye Cancer is recruiting above its size-band peers.
2 of 3 indexed trials (66.7%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
3 total, page 1 of 1
Evaluation of the Safety, Efficacy, and Pharmacokinetics of NBM-BMX in Patients With Metastatic Uveal Melanoma
Novelwise Pharmaceutical Corporation
NCT07136181
Suprachoroidal Administration in Subjects With Metastases to the Choroid
Aura Biosciences
NCT06643884
MRI in Diagnosing Solid Tumors of the Eye and Orbit
University of Cincinnati
NCT01653080
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Eye Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Eye Cancer trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Eye Cancer page
3 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 2 Eye Cancer trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Novelwise Pharmaceutical Corporation sponsors the most Eye Cancer trials on record, review their full trial history before evaluating a specific study. See Novelwise Pharmaceutical Corporation's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Eye Cancer condition card totals 3 registered trials; most-linked intervention dynamic contrast-enhanced MRI; top US site state Tennessee. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.